EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immunotherapy for endometrial cancer

Michiko Wada, Wataru Yamagami

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-024-02568-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Michiko Wada und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku-Ku, Tokyo, 160-8582, Japan. michikowada1216@g…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced recurrent endometrial cancer (EC) has a poor prognosis and new treatment options are needed. In 2013, EC was classified by genomic analysis into four groups: the POLE ultra-mutated group, the MSI-high hypermutated group (MSI-H), the copy number low group, and the copy number high group. The prognosis differs based on the classification, which should enable the individualization of treatment. The MSI-H and POLE types can induce PD-L1 expression in cancer cells. Among the gynecological cancers, EC exhibits the highest levels of PD-1 and PD-L1 expression and has the highest proportion of MSI-H. Thus, an immune checkpoint inhibitor (ICI) is expected to be effective. The first ICI to show efficacy in recurrent EC was the anti-PD1 antibody pembrolizumab, which exhibited efficacy in MSI-H EC. The combination of pembrolizumab and the multi-kinase inhibitor lenvatinib significantly prolongs OS/PFS compared with single-agent chemotherapy in previously treated recurrent EC, regardless of MSI status. ICIs are now moving from second-line and beyond to first-line treatment regimens. The efficacy of paclitaxel plus carboplatin (TC) and ICI combinations compared with TC have been demonstrated, including an ongoing Phase III trial comparing chemotherapy with the combination of pembrolizumab and lenvatinib. Although ICIs are becoming the mainstay of EC, they cause systemic inflammatory side effects known as irAEs. The incidence of irAEs is higher for combination therapy with CT or lenvatinib compared with ICI therapy alone. Even though they are rarely fatal, irAEs should be addressed promptly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsImmune Checkpoint InhibitorsImmunotherapyHumansFemaleAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Endometrial cancerImmune checkpoint inhibitorsPembrolizumab

Substanzen

Immune Checkpoint InhibitorspembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku-Ku, Tokyo, 160-8582, Japan. michikowada1216@gmail.com.
  • Department of Obstetrics and Gynecology, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku-Ku, Tokyo, 160-8582, Japan.

Zitieren

APA

Wada, M., & Yamagami, W. (2025). Immunotherapy for endometrial cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02568-2

Vancouver

Wada M, Yamagami W. Immunotherapy for endometrial cancer. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02568-2

BibTeX
@article{Wada2025,
  author = {Wada, Michiko and Yamagami, Wataru},
  title = {Immunotherapy for endometrial cancer},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-024-02568-2}
}
Kostenlos starten →